Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Inclusion Criteria: 1. Females with age between 18 to 70 years old; 2. Histologically confirmed triple negative breast cancer; 3. No more than one-line prior treatment for locally advanced or metastatic breast cancer; 4. Have at least one measurable lesion as per the RECIST criteria (version 1.1); 5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one; 6. Patients with life expectancy of at least 3 months; 7. Bone marrow function：neutrophils (≥1.5×10\^9/L), platelets (≥100×10\^9/L), hemoglobin (≥90 g/L); 8. Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's syndrome ≤ 2.5 × ULN; 9. Patients had good compliance with the planned treatment, understood the research process and written informed consent. Exclusion Criteria: 1. Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores; 2. Brain metastasis; 3. Recurrence or metastasis within 6 months after capecitabine withdrawal; 4. Recurrence or metastasis within 6 months after platinum withdrawal; 5. Progression in the treatment, recurrence or metastasis of paclitaxel (including albumin paclitaxel) within 6 months; 6. Patients required clinical intervention with gastrointestinal bleeding, gastrointestinal obstruction and non-feeding; 7. Patients who had Grade 2 or above Peripheral neuropathy; 8. Patients with severe systemic infection or other serious diseases; 9. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants; 10. Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; 11. Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial; 12. Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given; 13. The researchers considered the patients who were not suitable for enrollment.